6 results about "Membrane bound protein" patented technology

Immune cells engineered to express a chimeric antigen receptor (CAR) along with a TGF-beta dominant negative receptor (TGFβ DNR) and / or a membrane-bound IL15 protein (mbIL 15) are provided which are suitable for the treatment of diseases such as cancer.

Provided are novel fusion proteins, nucleic acids encoding said proteins, vectors comprising said nucleic acids, compositions comprising said nucleic acids or vectors, host cells comprising said nucleic acids, vectors or compositions or pharmaceutical compositions. Provided are methods of reducing (down regulating) a target membrane-bound protein (MBP) level in a cell, methods of producing a cell having a reduced target membrane-bound protein level, or methods of treating a disease, or methods of reducing or preventing GvHD in a subject associated with the administration of one or more CAR T-cells to the subject.

Immune cells engineered to express a chimeric antigen receptor (CAR) along with a TGF-beta dominant negative receptor (TGF|3 DNR) and / or a membrane-bound IL15 protein (mbIL15) are provided which are suitable for the treatment of diseases such as cancer.

There remains a need to provide healthcare professionals treating cancer, particularly advanced or metastatic solid tumors, with more and better options. [Solution] The present invention relates to the field of binding molecules. Specifically, the present invention relates to the field of therapeutic binding molecules for the treatment of diseases involving abnormal cells such as cancer cells. In particular, the present invention relates to multispecific antibodies that bind to the extracellular portion of two or more different membrane-bound proteins and thereby modulate the biological activity expressed by the cells, and to the use of such antibodies in combination therapy.

A method of expanding natural killer cells, comprising: providing a population of internal colloidal cells, wherein each internal colloidal cell comprises an internal colloidal volume and a fluid cell membrane comprising one or more membrane-bound proteins, each or collectively of which is capable of stimulating expansion of natural killer (NK) cells; and culturing a population of cells comprising NK cells capable of responding to the one or more membrane-bound proteins with the population of internal colloidal cells under conditions that allow expansion of the NK cells.